Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics Inc - Ordinary Shares - Class A

VERA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.15B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Vera Therapeutics Inc - Ordinary Shares - Class AVera Therapeutics Inc - Ordinary Shares - Class A-5--125%-0.2
$60.00

Target Price by Analysts

99.8% upsideVera Therapeutics Target Price DetailsTarget Price
$4.32

Current Fair Value

85.6% downside

Overvalued by 85.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.15 Billion
Enterprise Value$2.17 Billion
Earnings per Share$-4.66
Beta0.95
Outstanding Shares72,126,588

Return

Return on Equity-124.65%ROE
Return on Assets-89.17%
Return on Invested Capital-100.02%

Valuation & Multiples

P/E Ratio-5.05P/E Ratio
PEG-30.21PEG
Price to Sales-Price to Sales
Price to Book Ratio7.51Price to Book Ratio
Enterprise Value to Revenue210.81
Enterprise Value to EBIT-5.28
Enterprise Value to Net Income-6
Total Debt to Enterprise0.03
Debt to Equity0.23Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
-$1.30
Est. -$1.62
Revenue
$10.28 M
Est. $3.42 M

Next Earnings Call

Expected Date
February 25, 2027
EPS Estimate
-$1.51
Consensus analyst estimate
Revenue Estimate
$16.92 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 67.43%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %12.56%▼ 96.69%
Total Invested$291.41M▼ 91.34%
Investors Holding66▼ 168.00%

About Vera Therapeutics Inc

19 employees

Vera Therapeutics Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in Vera Therapeutics. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions and 3 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 8 open-market insider sales for Vera Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.